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Abstract
Introduction. High systolic blood pressure (SBP) is a well-known risk factor for major adverse cardiovascular out-
comes; however, data regarding disease burden due to high SBP in the Polish population are scarce.
Material and methods. We extracted and analyzed the latest country-, gender-, age- and year-specific estimates from 
the Global Burden of Disease (GBD) Study 2016 for SBP-related mortality, years of life lost (YLLs), disability-ad-
justed life years (DALYs), and attributable risk factors in Poland in 2016. In the GBD 2016, the term ‘high SBP’ 
refers to SBP of at least 110−115 mmHg.
Results. High SBP was attributable to (per 100,000) 106,043.16 deaths (95% UI [Uncertainty Interval]: 88,207–
121,849) that was 27.22% of all deaths in Poland in 2016; 1,751,844.69 DALYs (95% UI: 1,525,188–1,966,25) 
and 1,497,959.71 YLLs (95% UI: 1,287,279–1,497,959). In males, DALYs attributable to high SBP were higher by 
34% and YLLs by 23%, while in females death rates were higher by 14%. SBP was highly attributable to ischemic 
heart disease, stroke, and chronic kidney disease (63.7%, 63,1%, and 59.1%, respectively). In the GBD hierarchy, 
high SBP was the most common risk factor, followed by smoking, high body mass index (BMI), high total choles-
terol levels, alcohol use, and high fasting plasma glucose levels. 
Conclusions. In Poland, SBP of at least 110–115 mmHg remains one of the largest risks for loss of good health; 
greater than smoking, high cholesterol levels, or high BMI. With the population aging globally, the burden due to 
high SBP is expected to increase further.
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Introduction
Elevated systolic blood pressure (SBP) is a well-
known risk factor for major adverse cardiovascular 
outcomes, including stroke, myocardial infarction, 
heart failure, and peripheral artery disease. With the 
exception of spurious isolated systolic hypertension 
in young individuals and isolated systolic hyperten-
sion in certain endocrine disorders, high SBP typi-
cally reflects thickening and stiffness of large arteries, 
frequently seen in the elderly. The vast majority of 
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current guidelines have recommend an SBP value 
of 140 mmHg as a cut-off for diagnosis and optimal 
treatment of arterial hypertension [1, 2]; however, 
the precise subpopulation(s) and target(s) for the 
appropriate use of antihypertensive treatment remain 
under debate. The SPRINT Trial demonstrated sig-
nificant reductions in mortality in patients with high 
cardiovascular risk upon receipt of intensive blood 
pressure reduction therapy and achievement of an 
average SBP below 120 mmHg [3, 4]. Similarly, 
two large meta-analyses showed reductions in car-
diovascular-related deaths for a target SBP as low as 
120 mmHg [5, 6]. Other studies have found an SBP 
of at least of 110 mmHg has to be related to many 
cardiovascular and renal outcomes [7, 8], increased 
death rates, and higher disability-adjusted life years 
(DALYs) [9, 10]. DALYs measurement is a common 
index to quantitate overall burden of disease, ex-
pressed as the number of years of life lost (YLLs) and 
the years lived with disability (YLD) [11]. A number 
of risk factors are known to contribute to elevated 
SBP and related comorbidities, including ageing, 
high cholesterol levels, smoking, hyperglycemia, obe-
sity, high sodium diet, and lead exposure; however, 
data regarding the burden of elevated SBP attribut-
able to DALYs and YLLs in the Polish population are 
scarce. Accurate estimates of deaths attributable to 
elevated SBP, disease burden at the population level, 
and risk factors for related disability appear necessary 
to effectively manage this condition in Poland.
In the present report, we extracted and analyzed 
the latest country-, sex-, age- and year-specific esti-
mates from the Global Burden of Disease (GBD) 
study — a comprehensive platform for understand-
ing the main drivers of poor health at international, 
national, and local levels — for SBP-related mor-
tality, YLLs, DALYs, and attributable risk factors in 
Poland.
Material and methods
The GBD Study
The present report is part of the GBD 2016 compar-
ative risk assessment to assess health loss-related to 
specific risk factors [12−15]. In contrast to cross-sec-
tional or primary studies that analyze individual re-
cords to evaluate the number of people with high or 
normal SBP and related burden, the GBD project 
provides a descriptive meta-analysis of available study 
results and other medical records. Hence, the GBD 
data are projections at the population level rather than 
direct estimates for a specific sample and should be 
evaluated considering the availability and reliability 
of primary data for a given country (or region) and 
year, uncertainty of the pooled estimates, and the 
overall modeling and assumptions [10].
Burden related to SBP
In the GBD study, the term ‘elevated SBP’ refers to 
an SBP of at least 110 to 115 mmHg. On the basis 
of analysis from pooled cohort studies, in the GBD 
2016 the following diseases were identified as having 
sufficient evidence to support a relationship with 
high SBP: ischemic heart disease, ischemic stroke, 
hemorrhagic stroke, hypertensive heart disease, car-
diomyopathy, atrial fibrillation, aortic aneurysm, 
rheumatic heart disease, peripheral vascular disease, 
endocarditis, chronic kidney disease, and other car-
diovascular diseases. Although the cause of rheumatic 
heart disease and endocarditis is infection, high SBP 
has been associated with an increasing risk of death, 
accelerating adverse heart effects caused by infection 
or autoimmune response [12].
Computing methods
SBP-related deaths and DALYs were computed 
by multiplying a country-, age-, sex-, year-, and 
cause-specific population-attributable fraction by 
the estimated deaths or DALYs for the same strata as 
described elsewhere [10, 13, 15]. The main method 
used in the fatal outcomes and YLLs estimation was 
Cause of Death Ensemble modelling (CODEm) [13]. 
Non-fatal outcomes for a disease were analyzed using 
the Bayesian meta-regression tool the Disease Mod-
el-Meta Regression (DisMod-MR 2.1.) [15]. Death 
rate and DALYs were determined using the updated 
GBD 2016 global age-standard population [13].
Using the GBD results standard tool [16], from 
the GBD 2016 estimates we obtained the estimates 
for burden of elevated SBP in Poland in 2016. This 
tool provides access to complete set of age and gen-
der-specific estimates of burden across a wide range 
of causes. Data were shown as the number of preva-
lent cases per 100,000 along with 95% uncertainty 
interval (UI), which captures uncertainty from sam-
pling, non-sampling error from the study designs or 
diagnostic methods, model parameter uncertainty, 
and uncertainty regarding model specification. UIs 
were generated by taking 1,000 draws from the pos-
terior distribution of each estimate, with upper and 
lower bounds determined by the 25th and 97.5th va-
lues of the draws as described elsewhere [17]. Larger 
uncertainty intervals can result from limited data 
availability, small studies, and conflicting data, while 
smaller uncertainty intervals can result from exten-
sive data availability, large studies, and data that are 
consistent across sources.
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Risk factors
SBP-attributable risk factors were estimated based 
on risk factor prevalence using comparative risk as-
sessment; this tool allows the estimation of the level 
of mortality and disability related to SBP that can 
be attributed to past exposure risk [15]. In the GBD 
study, risk factors were categorized as environmental/ 
/occupational, behavioral, and metabolic. Attribut-
able burden is defined as the share of the burden 
of a disease that can be estimated to occur due to 
exposure to a particular risk factor. Diet high in so-
dium is defined as consumption of more than 1,000 
mg of sodium per day. Diet high in sugar-sweetened 
beverages is defined as consumption of any beverage 
with ≥ 50 calories of sugar per one-cup serving, in-
cluding carbonated beverages, sodas, energy drinks, 
fruit drinks but excluding 100% fruit and vegetable 
juices. Diet low in fruits is defined as consumption 
of less than 3 servings (11 ounces total) of fruits per 
day (includes fresh, frozen, cooked, canned, or dried 
fruit but excludes fruit juices and salted or pickled 
fruits). Diet low in nuts and seeds is defined as 
consumption of less than 4 servings (4 ounces total) 
of nuts and seeds per week, such as peanut butter. 
Diet low in whole grains is defined as consumption 
of less than 2.5 servings (4 ounces total) per day of 
whole grains (bran, germ, and endosperm in their 
natural proportions) from breakfast cereals, bread, 
rice, pasta, biscuits, muffins, tortillas, pancakes, and 
others. High body mass index is defined as above 
21.0–23.0 kg/m2.
The study utilized existing data from the GBD 
2016 Study and did not require ethical approval. The 
GBD 2016 Study complies with the Guidelines for 
Accurate and Transparent Health Estimates Report-
ing (GATHER) recommendations [18]. The GBD 
2016 estimates are freely available in an interactive 
data downloading tool on the Global Health Data 
exchange (GHDx) at: https://vizhub.healthdata.org/
gbd-compare/. The GHDx includes data for causes, 
risks, cause‐risk attribution, aetiologies, and impair-
ments.
Table I. Total number of DALYs, YLL and deaths attributable to high systolic blood pressure due to all causes, both sexes combined
Measure Number Percent of total
Disability-adjusted life years 1,751,844.69
(1,525,188.94–1,96625.83)
14.82
(12.9–16.82)
Years of life lost 1,497,959.71
(1,287,279.99–1,497,959.71)
22.09
(19.79–24.3)
Deaths 106,043.16
(88,207.45–121,849.82)
27.21
(23.25–30.03)
Data are numbers (95% UIs)
Results
Deaths, DALYs and YLLs attributable to SBP 
by cause
The total number of DALYs, YLLs and deaths in 
2016 attributable to high SBP of all causes are shown 
in Table I. In total, the number of deaths attribut-
able to high SBP was 106,043, which accounted for 
27.22% of all deaths in Poland in 2016. The total 
DALYs attributable to high SBP of all causes were 
higher by 34% in males (1,003,369 vs. 748,515 
in males and females, respectively). Similarly, the 
total YLLs were greater in males by 23% (752,639 
vs. 611,533 in males and females, respectively). In 
contrast, the death rates were greater in females by 
13.6% (49,651 vs. 56,392 in males and females, 
respectively). 
The percentage risk attribution of SBP to DALYs 
of cardiovascular outcomes is shown in Table II. As 
per GBD definition, hypertensive heart disease was 
fully attributable to high SBP; overall, hypertensive 
heart disease accounted for less than 1% of DALYs 
of all causes. Among other outcomes, SBP was high-
ly attributable to ischemic heart disease, stroke, and 
chronic kidney disease (63.7%, 63,1%, and 59.1%, 
respectively), with a slightly stronger attribution to 
ischemic heart disease- and stroke-DALYs in males, 
and no clear gender predilection to chronic kidney 
disease. In males, SBP showed a higher attribution to 
atrial fibrillation/flutter, aortic aneurysm, endocardi-
tis, peripheral artery disease, and other cardiovascu-
lar diseases, with the exception of cardiomyopathy, 
to which an SBP attribution was higher in females. 
Among all cardiovascular outcomes, ischemic heart 
disease had the largest impact on total DALYs (13%); 
and similarly, had a large impact on the total YLLs 
(Table III) and death rate (Table IV). Overall, SBP 
contributed to YLLs and deaths associated with car-
diovascular outcomes in a similar pattern as to DALYs.
As expected, the total DALYs, YLLs, and death 
rates attributable to high SBP increased with age, 
as shown in Table V; however, regardless of age, 
arterial hypertension 2018, vol. 22, no. 2
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Table II. DALYs attributable to high systolic blood pressure
Cardiovascular outcomes Risk attribution (%) % of total DALYs  
(Both sexes)All Males Females
Hypertensive heart disease 100 100 100 0.67
(0.54–1.09)
Ischemic heart disease 63.68
(54.46–72.05)
65.47
(57.71–72.63)
61.09
(49.26–72.54)
12.96
(11.56–14.47)
Stroke 63.08
(54.76–70.19)
66.67
(58.7– 3.1)
59.26
(50.12–67.57)
5.53
(4.90–6.16)
Chronic kidney disease 59.1
(51.32–66.32)
58.75
(50.81–66.58)
59.45
(51.9–66.22)
1.05
(0.98–1.12)
Atrial fibrillation and flutter 46.27
(40.24–51.97)
48.29
(42.62–53.57)
45.0
(38.4–51.18)
0.5
(0.4–0.6)
Aortic aneurysm 47.59
(40.66–53.98)
48.79
(41.68–54.98)
44.32
(36.77–51.2)
0.35
(0.3–0.41)
Endocarditis 45.48
(37.32–52.61)
47.68
(38.79–55.04)
41.09
(32.99–48.14)
0.093
(0.073–0.13)
Peripheral artery disease 34.07
(26.57–41.92)
35.57
(27.94–42.92)
32.21
(29.04–41.0)
0.3
(0.22–0.4)
Cardiomyopathy and myocarditis 29.05
(22.50–36.27)
25.15
(19.11–35.34)
34.52
(25.88–45.26)
1.64
(1.28–1.91)
Other CV and circulatory diseases 51.73
(47.42–56.64)
54.42
(49.99–59.12)
48.48
(43.69–53.15)
1.37
(1.25–1.5)
Data are percentages (95% UIs)
Table III. YLLs attributable to high systolic blood pressure
Cardiovascular outcomes Risk attribution [%] Percent of total YLL 
(Both sexes)All Males Females
Hypertensive heart disease 100 100 100 0.96
(0.76–1.65)
Ischemic heart disease 63.71
(54.45–72.17)
65.49
(57.71–72.71)
61.06
(48.74–72.58)
20.97
(20.11–21.91)
Stroke 63.75
(55.74–70.72)
67.38
(59.75–73.95)
59.59
(50.36–67.77)
7.63
(7.13–8.18)
Chronic kidney disease 59.78
(51.85–67.17)
59.09
(50.98–66.96)
60.7
(52.92–67.66)
1.08
(1.03–1.15)
Atrial fibrillation and flutter 42.87
(35.43–49.83)
43.92
(36.97–50.32)
42.33
(34.44–49.9)
0.38
(0.29–0.47)
Aortic aneurysm 47.59
(40.66–50.63)
48.79
(41.68–54.96)
44.32
(36.77–51.2)
0.61
(0.56–0.67)
Endocarditis 45.52
(37.34–52.64)
47.7
(38.83–55.05)
41.08
(33.01–48.13)
0.16
(0.13–0.23)
Peripheral artery disease 33.97
(26.56–41.8)
35.55
(27.91–42.95)
31.74
(23.55–40.96)
0.45
(0.31–0.62)
Cardiomyopathy and myocarditis 28.85
(22.36–36.63)
25.04
(18.92–35.71)
34.54
(26.02–45.51)
2.62
(2.02–2.95)
Other CV and circulatory diseases 51.9
(47.58–56.59)
54.69
(50.18–59.49)
48.21
(43.12–52.95)
1.37
(1.26–1.5)
Data are percentages (95% UIs)
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Table VI. Deaths attributable to high systolic blood pressure
Cardiovascular outcomes Risk attribution (%) Percent of total deaths 
(Both sexes)All Males Females
Hypertensive heart disease 100 100 100 1.26
(0.98–2.24)
Ischemic heart disease 60.13
(46.79–72.72)
61.56
(51.26–71.55)
58.87
(42.61–73.42)
28.72
(27.69–29.91)
Stroke 57.9
(48.39–67.12)
61.8
(53.24–69.32)
55.04
(43.86–66.29)
9.19
(8.48–9.93)
Chronic kidney disease 65.07
(57.35–71.77)
63.58
(55.89–70.9)
66.65
(59.36–73.08)
1.21
(1.15–1.29)
Atrial fibrillation and flutter 39.13
(30.46–47.5)
38.98
(30.99–46.77)
39.2
(30.28–47.95)
0.72
(0.55–0.91)
Aortic aneurysm 44.36
(36.75–51.52)
45.74
(38.25–52.61)
41.4
(32.79–49.91)
0.58
(0.53–0.63)
Endocarditis 44.49
(36.23–52.4)
46.71
(38.34–53.67)
41.26
(32.61–50.93)
0.12
(0.099–0.18)
Peripheral artery disease 31.12
(22.83–40.39)
32.98
(25.39–41.13)
29.5
(20.12–40.55)
0.64
(0.43–0.91)
Cardiomyopathy and myocarditis 31.43
(22.69–42.52)
27.91
(20.56–37.14)
34.35
(23.6–50.06)
3.27
(2.32–3.78)
Other CV and circulatory diseases 47.75
(42.56–52.89)
50.91
(46.17–55.82)
44.82
(38.67–51.03)
1.39
(1.27–1.52)
Data are percentages (95% UIs)
the rates of DALYs were 2−4 times higher in males 
than in females. Males also had higher rates of YLLs 
among the age groups, with the exception of the 
group consisting of individuals over 70 years old, 
in which the rates were comparable. Overall, the 
gender differences in YLLs were smaller than in 
DALYs. The death rates were higher in males, but 
only in the 15−49 and 50−69 age groups. In the old-
est age group (over 70 years old), the rates of both 
genders were comparable, which was similar for all 
ages combined.
Risk factors
At level 1 of the GBD hierarchy for risk factors, 
among all-cause deaths in Poland in 2016, 491.37 
per 100,000 (95% UI: 441.17–547.45) were at-
tributable to behavioral risks, 428.71 per 100,000 
(95% UI: 383.24–476.73) to metabolic risks, and 
99.27 per 100,000 (95% UI: 86.98–113.9) to en-
vironmental and occupational risks. Table VI shows 
the leading level 3 risk factors for all-cause deaths, 
DALYs, and YLLs in Poland for both genders com-
bined. High SBP occupied the first position in the 
GBD 2016 hierarchy, resulting in 27% of deaths, 
almost 15% of DALYs, and 14% of YLLs. On the 
second to fifth positions were smoking, high body 
mass index, high total cholesterol levels, and alcohol 
use, respectively. 
Among all combined deaths for all ages and both 
genders due to SBP-related cardiovascular outcomes 
including hypertensive heart disease, ischemic heart 
disease, stroke, cardiomyopathy, atrial fibrillation, 
aortic aneurysm, rheumatic heart disease, peri -
pheral vascular disease, endocarditis, chronic kidney 
disease, and other cardiovascular diseases, the lead-
ing attributable risk factors, aside from high SBP, 
were high fasting plasma glucose levels, smoking, 
alcohol use, high body mass index, and a high-salt 
diet, as well as, rather unexpectedly, lead exposure 
(Table VII).
Discussion
To the best of our knowledge, this is the first report 
evaluating the burden associated with an SBP of at 
least 110−115 mmHg in Poland using the GBD 
Study 2016. We found that elevated SBP contribut-
ed to 106,043 deaths (27% of all deaths in Poland 
in 2016), nearly 1.5 million YLLs, and over 1.7 mil-
lion DALYs. Furthermore, we found that ischemic 
heart disease and stroke accounted for the majority 
of loss of good health (deaths, DALYSs, and YLLs) 
related to an SBP of at least 110−115 mmHg. SBP 
also showed a high causality of chronic kidney dis-
ease, atrial fibrillation and flutter, aortic aneurysm, 
arterial hypertension 2018, vol. 22, no. 2
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Table V. DALYs and YLLs and death rates per 100,000 attributable to high systolic blood pressure by sex and age
Age group All Males Females
DALYs
5–14 0.74
(0.53–0.99)
0.73
(0.48–1.03)
0.75
(0.55–1.01)
15–49 656.73
(531.33–782.63)
1,020.63
(820.58–1,239.21)
282.38
(219.42–350.51)
50–69 7,650.34
(6,657.55–8,547.11)
11,451.31
(9,724.35–13,142.52)
4,239.92
(3,586.4–4,866.86)
70+ 21,266.68
(17,696.11–24,482.38)
24,568.3
(20,363.76–28,959.65)
19,416.6
(15,687.05–22.773.36)
All ages 4,533.65
(3,946.99–5.088.43)
5,368.31
(4,619.42–6,131.77)
3,751.73
(3,138.11–4,297.36)
YLLs
5–14 0.03
(0.015–0.053)
0.033
(0.016–0.059)
0.023
(0.013–0.047)
15–49 108.54
(72.59–148.57)
131.86
(89.11–180.79)
84.56
(56.63–117.7)
50–69 1,114.85
(792.18–1,469.36)
1,282.66
(915.57–1,704.91)
964.28
(678.68–1,256.22)
70+ 3,004.06
(2,184.14–3,929.36)
2,955.81
(2,160.03–3,855.57)
3,031.1
(2,197.25–3,973.4)
All ages 657.13
(473.51–855.69)
625.68
(448.2–817.34)
868.58
(494.04–888.85)
Deaths
5–14 0.0092
(0.0066–0.013)
0.0091
(0.0059–0.013)
0.0094
(0.0069–0.013)
15–49 12.57
(10.15–15.26)
20.34
(15.99–25.09)
4.59
(3.55–5.77)
50–69 250.57
(218.05–283.16)
385.73
(328.16–448.93)
129.3
(108.91–150.37)
70+ 1,948.68
(1,566.87–2,335.33)
2,036.69
(1,630.38–2,437.7)
1,930.26
(1,505.62–2,329.83)
All ages 274.43
(228.27–315.33)
265.65
(223.3–311.0)
282.65
(226.3–335.42)
endocarditis, peripheral artery disease, cardiomyopa-
thy, and other cardiovascular diseases.
Although the total number of DALYs, YLLs and 
deaths in both genders was age-dependent in the pres-
ent study, the vast majority of the rates were higher in 
males than in females. This finding may suggest that 
females have better health-seeking behavior, are more 
sensitive to information regarding healthy life styles, 
and have better access to all aspects of primary pre-
vention of cardiovascular disease. Similar suggestions 
also arose from estimates for the GBD Study 2013 
regarding ischemic heart disease [19] and stroke [20].
In Poland in 2016, an SBP of at least 110−115 
mmHg was ranked number 1 in terms of deaths 
attributable to risk factors (27% of all deaths), fol-
lowed by smoking, high cholesterol levels, and high 
body mass index. An unhealthy diet and pollution 
were also highly ranked. Other common risk factors 
in Poland included high fasting blood glucose levels, 
alcohol use, a high-salt diet, lead exposure, a diet low 
in fruits, fiber, omega-3 and vegetables, exposure to 
occupational carcinogens, and low physical activity. 
These findings demonstrate that there is huge poten-
tial for risk prevention to reduce the deaths, DALYs, 
and YLLs attributable to high SBP, since all the risk 
factors included in the present report are modifiable.
Although the GBD 2016 approach was based on 
the most comprehensive data from 1990 to 2016 and 
utilized the latest advances in modelling techniques 
and strategy, it had some limitations, as described 
elsewhere [12–14], which also apply to the present 
report. Firstly, an SBP of 110−115 mmHg was used 
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in the GBD Study 2016, corresponding to optimal 
blood pressure, i.e. below the threshold for diag-
nosis of hypertension and use of antihypertensive 
therapies [1]. The SPRINT trial [3, 21] and recent 
meta-analysis [5] have demonstrated a significant 
reduction in mortality among individuals with high 
cardiovascular risk upon receipt of intensive blood 
pressure lowering therapy and achievement of an 
average SBP below 120 mmHg; however, other stud-
ies have yielded contradicting results [22, 23]. The 
present results do not help to resolve the important 
debate about appropriate clinical use and targets for 
antihypertensive treatments, they confirm only the 
model assumption that an SBP of 110−115 mmHg 
is a modifiable risk factor for mortality and loss of 
good health, but cannot determine the optimal SBP 
for the Polish population. Secondly, in the GBD 
Study 2016 high diastolic blood pressure was not 
included in the analyses. Thirdly, GBD analyses of 
SBP in Poland, as in other countries, could be affected 
by the allocation of garbage codes as well as incorrect 
mapping to the ICD-10 codes, for example heart fail-
ure instead of ischemic heart disease.
Since both the projected number and prevalence 
rate of an SBP of at least 110−115 mmHg are likely to 
continue to increase globally [10], the present study has 
some potential implications for the Polish population. 
Policies and strategies should be guided by the com-
parative importance of health loss from exposure to an 
SBP of at least 110–115 mmHg and other major risk 
factors for cardiovascular outcomes, aiming to mitigate 
disease burden through the optimal control of high 
SBP and a combination of behavioral, lifestyle, and 
drug treatment strategies.
In conclusion, the present study demonstrates that 
an SBP of at least 110−115 mmHg remains one of the 
largest risks for loss of good health in Poles; greater than 
smoking, high cholesterol levels, and high body mass 
index. With the population aging and the fact that SBP 
levels increase with age globally [10], the number of in-
dividuals with hypertension and related adverse health 
outcomes is expected to increase in Poland.
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